Patient demographics, clinical characteristics, and previous treatment at baseline (ITT population)
| Combined placebo group (n = 73) | IFNβ, 2.2 μg (n = 67) | IFNβ, 44 μg (n = 68) | All patients (n = 208) | |
|---|---|---|---|---|
| Values are mean (SD) and range, or per cent. | ||||
| CCP, cyclic citrullinated peptide; DMARD, disease modifying anti-rheumatic drug; ITT, intention to treat; MTX, methotrexate. | ||||
| Demographics | ||||
| Age (years) | 53.6 (11.7) | 53.7 (12.8) | 52.0 (11.1) | 53.1 (11.9) |
| Age range (years) | 25.1 to 81.4 | 28.0 to 79.0 | 29.3 to 77.9 | 25.1 to 81.4 |
| Female | 65.8% | 83.6% | 83.8% | 77.4% |
| Disease status | ||||
| Mean duration (years) | 4.1 (2.4) | 4.2 (2.7) | 4.2 (2.7) | 4.2 (2.6) |
| Duration range (years) | 0.6 to 9.5 | 0.6 to 12.5 | 0.5 to 10.4 | 0.5 to 12.5 |
| Rheumatoid factor positive | 71.2% | 65.2% | 65.2% | |
| Anti-CCP positive | 54.8% | 58.2% | 55.9% | |
| Functional class I | 15.1% | 13.4% | 17.6% | |
| Functional class II | 57.5% | 62.7% | 72.1% | |
| Functional class III | 24.7% | 22.4% | 10.3% | |
| Functional class IV | 2.7% | 1.5% | 0 | |
| Concomitant MTX treatment | ||||
| MTX dose (mg/week) | 15.3 (4.6) | 14.7 (5.5) | 15.2 (5.1) | 15.1 (5.0) |
| Length of MTX use (months) | 19.0 (14.1) | 16.4 (13.6) | 17.1 (13.8) | 17.6 (13.8) |